Park Avenue Securities LLC Has $2.81 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Park Avenue Securities LLC boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,050 shares of the biopharmaceutical company's stock after buying an additional 10,824 shares during the quarter. Park Avenue Securities LLC's holdings in Pfizer were worth $2,814,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PFE. San Luis Wealth Advisors LLC grew its holdings in shares of Pfizer by 18.0% in the 4th quarter. San Luis Wealth Advisors LLC now owns 32,175 shares of the biopharmaceutical company's stock worth $854,000 after purchasing an additional 4,900 shares during the last quarter. Allen Mooney & Barnes Investment Advisors LLC grew its stake in Pfizer by 14.4% during the fourth quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 25,851 shares of the biopharmaceutical company's stock worth $686,000 after buying an additional 3,256 shares during the last quarter. Rockland Trust Co. increased its holdings in shares of Pfizer by 6.2% during the fourth quarter. Rockland Trust Co. now owns 429,514 shares of the biopharmaceutical company's stock worth $11,395,000 after buying an additional 25,260 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its stake in shares of Pfizer by 19.2% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 88,519 shares of the biopharmaceutical company's stock valued at $2,348,000 after acquiring an additional 14,233 shares during the last quarter. Finally, Pines Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $306,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 0.7 %

Shares of NYSE PFE traded down $0.19 during midday trading on Friday, reaching $26.30. 35,146,711 shares of the stock were exchanged, compared to its average volume of 35,869,448. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The business has a 50-day simple moving average of $26.08 and a two-hundred day simple moving average of $27.99. The company has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer's quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.17) EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is presently 227.03%.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company's stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Wolfe Research assumed coverage on Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective for the company. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Bank of America reaffirmed a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.